IMNM
Immunome Inc.
$19.57
+$0.08(+0.41%)
60
Overall
50
Value
83
Tech
47
Quality
Market Cap
$1.41B
Volume
1.42M
52W Range
$5.15 - $20.46
Target Price
$25.67
Company Overview
| Mkt Cap | $1.41B | Price | $19.57 |
| Volume | 1.42M | Change | +0.41% |
| P/E Ratio | -4.8 | Open | $19.67 |
| Revenue | $9.0M | Prev Close | $19.49 |
| Net Income | $-293.0M | 52W Range | $5.15 - $20.46 |
| Div Yield | N/A | Target | $25.67 |
| Overall | 60 | Value | 50 |
| Quality | 47 | Technical | 83 |
No chart data available
About Immunome Inc.
Immunome, Inc., a clinical-stage biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises of AL102, a gamma secretase inhibitor which is in phase 3 clinical trial for the treatment of desmoid tumors; IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates which is in phase 1 clinical trial; and preclinical asset consist of IM-3050, a fibroblast activation protein targeted radioligand therapy. It also develops solid tumor ADC drug candidates which includes IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Latest News
Lake Street Sticks to Their Buy Rating for Immunome (IMNM)
TipRanks Auto-Generated Intelligence Newsdesk•25 days ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | IMNM | $19.57 | +0.4% | 1.42M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |